Molecular Endocrinology, Vol 10, 45-56, Copyright © 1996 by Endocrine Society

ARTICLES

Development of a constitutively active mutant form of the prolactin receptor, a member of the cytokine receptor family

I Gourdou, L Gabou, J Paly, AY Kermabon, L Belair and J Djiane
Unite d'Endocrinologie Moleculaire, Institut National de la Recherche Agronomique, Jouy-en-Josas, France.

The extracellular domain of the PRL receptor (PRL-R) is composed of two subdomains of approximately 100 amino acids, S1 and S2. To explore the functional significance of these subdomains in PRL binding and signal transduction, deletion mutants of S1 or/and S2 subdomains were constructed. We report here the inability of each of these mutant receptor forms to bind PRL after expression in COS-7 cells. We also studied the abilities of these different mutant receptors to respond to hormonal stimulation after transfection of each mutant complementary DNA into CHO-K1 cells along with a chimeric gene containing the promoter of a milk protein gene (beta-lactoglobulin) fused to chloramphenicol acetyltransferase coding sequence. Somewhat unexpectedly, a constitutively (PRL-independent) mutant form of the PRL- R was obtained after deletion of the S2 subdomain. Moreover, we analyzed, in CHO-K1 cells, the biological activity of chimeric receptors constructs in which each subdomain sequence was replaced by an unrelated, but coding, sequence of foreign protein, and we confirmed a specific requirement for the S1 sequence in the constitutive activity. In contrast, the S2 subdomain produced an inhibitory effect on S1 constitutive activity. Cotransfection experiments with the wild- type receptor and the constitutive mutant receptor provided evidence that the wild-type receptor was able to inhibit the constitutive activity of the deleted mutant. Furthermore, in the mouse mammary epithelial cell line HC11, the constitutive PRL-R form was able to induce transcription of the beta-casein gene in the absence of PRL. These results suggest a complex signal transduction process that implicates each extracellular PRL-R subdomain. Possible mechanisms for the constitutive effect are discussed.

This article has been cited by other articles:

				R. L. Bogorad, C. Courtillot, C. Mestayer, S. Bernichtein, L. Harutyunyan, J.-B. Jomain, A. Bachelot, F. Kuttenn, P. A. Kelly, V. Goffin, et al. Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors PNAS, September 23, 2008; 105(38): 14533 - 14538. [Abstract] [Full Text] [PDF]

				L. Bao, C. Tessier, A. Prigent-Tessier, F. Li, O. L. Buzzio, E. A. Callegari, N. D. Horseman, and G. Gibori Decidual Prolactin Silences the Expression of Genes Detrimental to Pregnancy Endocrinology, May 1, 2007; 148(5): 2326 - 2334. [Abstract] [Full Text] [PDF]

				D J Flint, M Boutinaud, C B A Whitelaw, G J Allan, and A F Kolb Prolactin inhibits cell loss and decreases matrix metalloproteinase expression in the involuting mouse mammary gland but fails to prevent cell loss in the mammary glands of mice expressing IGFBP-5 as a mammary transgene. J. Mol. Endocrinol., June 1, 2006; 36(3): 435 - 448. [Abstract] [Full Text] [PDF]

				I. Gourdou, J. Paly, C. Hue-Beauvais, L. Pessemesse, J. Clark, and J. Djiane Expression by Transgenesis of a Constitutively Active Mutant Form of the Prolactin Receptor Induces Premature Abnormal Development of the Mouse Mammary Gland and Lactation Failure Biol Reprod, March 1, 2004; 70(3): 718 - 728. [Abstract] [Full Text] [PDF]

				C. Stocco, J. Djiane, and G. Gibori Prostaglandin F2{alpha} (PGF2{alpha}) and Prolactin Signaling: PGF2{alpha}-Mediated Inhibition of Prolactin Receptor Expression in the Corpus Luteum Endocrinology, August 1, 2003; 144(8): 3301 - 3305. [Abstract] [Full Text] [PDF]

				J. B. Kline, M. A. Rycyzyn, and C. V. Clevenger Characterization of a Novel and Functional Human Prolactin Receptor Isoform ({Delta}S1PRLr) Containing Only One Extracellular Fibronectin-Like Domain Mol. Endocrinol., October 1, 2002; 16(10): 2310 - 2322. [Abstract] [Full Text] [PDF]

				J. Frasor, K. Park, M. Byers, C. Telleria, T. Kitamura, L.-y. Yu-Lee, J. Djiane, O.-K. Park-Sarge, and G. Gibori Differential Roles for Signal Transducers and Activators of Transcription 5a and 5b in PRL Stimulation of ER{alpha} and ER{beta} Transcription Mol. Endocrinol., December 1, 2001; 15(12): 2172 - 2181. [Abstract] [Full Text] [PDF]

				J. Frasor, U. Barkai, L. Zhong, A. T. Fazleabas, and G. Gibori PRL-Induced ER{alpha} Gene Expression Is Mediated by Janus Kinase 2 (Jak2) While Signal Transducer and Activator of Transcription 5b (Stat5b) Phosphorylation Involves Jak2 and a Second Tyrosine Kinase Mol. Endocrinol., November 1, 2001; 15(11): 1941 - 1952. [Abstract] [Full Text] [PDF]

				R. C. H. Lee, J. A. Walters, M. E. Reyland, and S. M. Anderson Constitutive Activation of the Prolactin Receptor Results in the Induction of Growth Factor-independent Proliferation and Constitutive Activation of Signaling Molecules J. Biol. Chem., April 9, 1999; 274(15): 10024 - 10034. [Abstract] [Full Text] [PDF]

				R. J. M. Ross, N. Esposito, X. Y. Shen, S. Von Laue, S. L. Chew, P. R. M. Dobson, M.-C. Postel-Vinay, and J. Finidori A Short Isoform of the Human Growth Hormone Receptor Functions as a Dominant Negative Inhibitor of the Full-Length Receptor and Generates Large Amounts of Binding Protein Mol. Endocrinol., March 1, 1997; 11(3): 265 - 273. [Abstract] [Full Text]

				T. J. Gonda and R. J. D'Andrea Activating Mutations in Cytokine Receptors: Implications for Receptor Function and Role in Disease Blood, January 15, 1997; 89(2): 355 - 369. [Full Text] [PDF]

				M. Sundstrom, T. Lundqvist, J. Rodin, LutzB. Giebel, D. Milligan, and G. Norstedt Crystal Structure of an Antagonist Mutant of Human Growth Hormone, G120R, in Complex with Its Receptor at 2.9AResolution J. Biol. Chem., December 13, 1996; 271(50): 32197 - 32203. [Abstract] [Full Text] [PDF]